REFERENCES
- Heron
M. Deaths: leading causes for 2015. Natl Vital Stat Rep 2017;66(5): 1–76.
- Lanks CW, Musani AI,
Hsia DW. Community-acquired Pneumonia and Hospital acquired Pneumonia.Med Clin North Am. 2019; 103(3): 487-501.
- Said MA, Johnson
HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, et al. AGEDD Adult
Pneumococcal Burden Study Team. Estimating the burden of pneumococcal
pneumonia among adults: a systematic review and meta-analysis of
diagnostic techniques. PLoS One 2013; 8(4): e60273.
- Mandell LA, Wunderink RG,
Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious
Diseases Society of America/American Thoracic Society consensus
guidelines on the management of community-acquired pneumonia in
adults. Clin Infect Dis 2007; 44(Suppl 2): S27–72.
- Quan TP, Fawcett
NJ, Wrightson JM, Finney J, Wyllie D, Jeffery K, et al. Infections in
Oxfordshire Research Database (IORD). Increasing burden of
community-acquired pneumonia leading to hospitalisation, 1998-2014.Thorax 446 2016; 71: 535-42.
- Mandell LA, Wunderink RG,
Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious
Diseases Society of America/American Thoracic Society consensus
guidelines on the management of community-acquired pneumonia in
adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
- Kocsis B, Domokos J,
Szabo D. Chemical structure and pharmacokinetics of novel quinolone
agents represented by avarofloxacin, delafloxacin, finafloxacin,
zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob2006; 15(1): 34.
- Yuan JY, Mo BW, Ma
Z, Lv Y, Cheng SL, Yang YP, et al. Investigator Group of the Phase 3
Study on Oral Nemonoxacin. Safety and efficacy of oral nemonoxacin
versus levofloxacin in treatment of community-acquired pneumonia: A
phase 3, multicenter, randomized, double-blind, double-dummy,
active-controlled, non-inferiority trial. J Microbiol Immunol
Infect 2019; 52(1):35-44.
- Guo BN, Wu XJ,
Zhang YY, Shi YG, Yu JC, Cao GY, et al. Safety and clinical
pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in
healthy Chinese volunteers following single and multiple oral doses.Clin Drug Investig 2012; 32(7):475-86.
- Chung DT, Tsai CY, Chen
SJ, Chang LW, King CH, Hsu CH, et al. Multiple-dose safety,
tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in
healthy volunteers. Antimicrob Agents Chemother 201054(1):411-7.
- Lin L, Chang LW, Tsai CY,
Hsu CH, Chung DT, Aronstein WS, et al. Dose escalation study of the
safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870),
a novel potent broad-spectrum nonfluorinated quinolone, in healthy
volunteers. Antimicrob Agents Chemother 2010; 54(1):
405-10.
- Qin XH, Huang HH. Review of
nemonoxacin with special focus on clinical development. Drug Des
Devel Ther 2014; 8: 765-74.
- Kang Y, Li Y,
Xu FY, Zhang J, Wang K, Chen YC, et al. Population Pharmacokinetics
Study of Nemonoxacin Among Chinese Patients with Moderate Hepatic
Impairment. Clin Ther 2019; 41(3): 505-517.
- Zhao CY, Lv Y,
Li XY, Hou F, Ma XZ, Wei MJ, et al. Effects of Nemonoxacin on Thorough
ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled
Crossover Study in Healthy Chinese Adults. Clin Ther. 2018;40(6): 983-992.
- Verbeeck RK, Musuamba
FT. Pharmacokinetics and dosage adjustment in patients with renal
dysfunction. Eur J Clin Pharmacol 2009; 65(8):
757-73.
- Liang W, Chen YC, Cao YR,
Liu XF, Huang J, Hu JL, et al. Pharmacokinetics and pharmacodynamics
of nemonoxacin against Streptococcus pneumoniae in an in vitro
infection model. Antimicrob Agents Chemother 2013;57(7): 2942-7.
- Guo BN, Zhang J, Yu JC, Wu XJ,
Shi YG, Tsai CY. A liquid chromatography-tandem mass spectrometry
assay for the determination of nemonoxacin (TG-873870), a novel
nonfluorinated quinolone, in human plasma and urine and its
application to a single-dose pharmacokinetic study in healthy Chinese
volunteers. Biomed Chromatogr 2012; 26(11): 1333-40.
- Lindbom L, Ribbing
J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM
related programming. Comput Methods Programs Biomed 2004;75: 85–94.
- Watson PE, Watson ID, Batt
RD. Total body water volumes for adult males and females estimated
from simple anthropometric measurements. Am J Clin Nutr 1980;
33: 27–39.
- Arkouche W,
Fouque D, Pachiaudi C, Normand S, Laville M, Delawari E, et al. Total
body water and body composition in chronic peritoneal dialysis
patients. J Am Soc Nephrol. 1997; 8(12): 1906-14.
- Wu XJ, Zhang J, Guo BN, Zhang YY, Yu JC, Cao GY, et al.
Pharmacokinetics and pharmacodynamics of multiple-dose intravenous
nemonoxacin in healthy Chinese volunteers. Antimicrob Agents
Chemother 2015;59 (3):1446-54. doi: 10.1128/AAC.04039-14.
- He GL, Guo BN, Yu JC, Zhang J,
Wu XJ, Cao GY, et al. Determination of a novel nonfluorinated
quinolone, nemonoxacin, in human feces and its glucuronide conjugate
in human urine and feces by high-performance liquid
chromatography-triple quadrupole mass spectrometry. Biomed
Chromatogr 2015; 29(5): 739-48.
- Chow CP, Tsai CY, Yeh CY and Chen SJ. In vitro metabolism and
interaction of nemonoxacin (TG-873870) on human hepatic CYP3A4. In:
Abstracts of the Four-seventh Interscience Conference on Antimicrobial
Agents and Chemotherapy, 2007; abstract A-27.
Table 1. Demographic characteristics of the subjects in
patients with severe renal impairment and healthy controls